Athersys Inc. Stock
Your prediction
Athersys Inc. Stock
Our community identified positive and negative aspects for Athersys Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Athersys Inc. stock. On the other hand our users think that "Unique positioning" could be a problem in the future.
Pros and Cons of Athersys Inc. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Athersys Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Athersys Inc. | - | - | - | - | - | - | - |
| Biocryst Pharmaceuticals | -1.040% | 6.900% | 7.459% | -31.214% | -5.949% | -35.251% | -30.843% |
| Heron Therapeutics Inc. | 0.970% | 1.061% | -21.875% | -39.099% | -10.233% | -59.283% | -93.364% |
| Madrigal Pharmaceuticals inc. | 0.050% | 3.064% | -3.583% | 28.338% | -16.329% | 46.866% | 312.766% |
Comments
Athersys, Inc. (NASDAQ: ATHX) is now covered by analysts at Alliance Global Partners. They set a "buy" rating on the stock.
Show more
Ratings data for ATHX provided by MarketBeat
